July 21, 2022

Name of listed company: Chugai Pharmaceutical Co., Ltd.

Code number:

4519 (Prime Market of Tokyo Stock Exchange)

Head office:

1-1,Nihonbashi-Muromachi2-Chome,Chuo-ku, Tokyo

President & CEO:

Osamu Okuda

Inquiries to:

Toshiya Sasai

Head of Corporate Communications Dept.

Tel: +81-(0)3-3273-0554

F. Hoffmann-La Roche Announces Half Year Results 2022

F. Hoffmann-La Roche Ltd. (hereafter "Roche") [Head Office: Basel, Switzerland. CEO: Severin Schwan] announced today its half year results 2022 (January 1 - June 30, 2022).

Roche owns 59.89% of Chugai's outstanding shares (61.14% of voting rights) as of the end of June 2022.

Its investor update and presentation materials can be found on its website (https://www.roche.com/).

Chugai's performance for the period of January 1 to June 30, 2022 is included in the announced Roche Group's results.

Investor Updates

Reporting

###

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Chugai Pharmaceutical Co. Ltd. published this content on 21 July 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 21 July 2022 05:13:01 UTC.